Accumulating evidence has suggested that perturbations in the PI3K-Akt-mTOR pathway occur in the vast majority of metastatic cancers; hence, PI3K-Akt-mTOR can be a potential therapeutic target (Huang et al., 2018). The gene discussed is MTOR; the disease is metastatic malignant neoplasm.